Abstract:Abstract Background and Aims Serum creatinine is not a sensitive biomarker for acute kidney injury (AKI) in neonates. Unlike creatinine, cystatin-C (Cys-C) does not cross the blood placental barrier and the serum level in the neonates is not significantly impacted by the gestation age, birthweight, and the age during the first four weeks after birth. Therefore, serum Cys-C may be a better marker neonatal AKI than serum creatinine. We aimed to assess the performance of serum Cys-C as an alternative biomarker for detecting neonatal AKI. Method This is a large multicenter cohort study including 52,333 hospitalized neonates. First, we assess the impacts of gestational age, birthweight, and days after birth on the level of Cys-C, and estimated the upper normal limit (UNL) and the reference change value RCV of serum Cys-C in neonates. Then, we proposed a Cys-C based criteria (CyNA) for detecting neonatal AKI based on both Cys-C level and the change in Cys-C using UNL and RCV as the cutoffs, respectively. Finally, we assessed the performance of CyNA in detecting neonatal AKI and the association of CyNA-detected AKI with the risk of in-hospital death, and compared the performance with that using the KDIGO creatinine criteria. Results Cys-C level in neonates did not vary with gestational age and birthweight, and remained relatively stable during the neonatal period (Figure 1). The UNL of Cys-C was 2.2 mg/L and the RCV (for Cys-C ratio) was 1.25. CyNA criteria defines AKI by a serum Cys-C of ≥2.2 mg/L (UNL) or an increase in Cys-C of ≥25% (RCV) during the neonatal period. Among 52,333 neonates 6,336 (12.1%) AKI cases were detected by CyNA criteria, of whom 96 (1.5%) died. In comparison, 202 (0.44%) death events occurred in 45,997 neonates who did not have AKI. After adjusting all comorbidities, CYNA-detected AKI was associated with a significantly increased risk of in-hospital mortality (adjusted HR 2.91, 95% confidence interval, 2.24 to 3.78). Among 45,839 neonates that had measurement of both Cys-C and SCr, 4,513 (9.8%) had AKI detected by CyNA only, 373 (0.8%) by KDIGO only, and 381 (0.8%) by both criteria (Table 1). After adjusting admission to ICU and comorbidities, AKI detected by CyNA only (C+/K-) was associated with a significantly increased risk of in-hospital mortality compared with those without AKI by both criteria (C-/K-), with an adjusted hazard ratio of 2.86 (95% CI, 2.02 to 4.04). In comparison, the HR for those detected by KDIGO only (C-/K+) was lower at 2.15 (95% CI, 0.96 to 4.81). Neonates with AKI detected by both criteria (C+/K+) had the highest risk of in-hospital mortality (HR 4.86, 95% confidence interval, 2.84 to 8.29). Conclusion Serum Cys-C is a robust and sensitive biomarker for detecting neonatal AKI. CyNA is 5.5 times more sensitive than the modified KDIGO in detecting neonates who are at an elevated risk of in-hospital mortality.

Change of cystatin C values in preterm infants with asphyxia-From two centers of China.

Diagnostic value of serum cystatin C for kidney injury induced by neonatal asphyxia

The Diagnostic Value of Blood β2 - microglobulin and Cystatin - C in Early Kidney Impairment after Neonatal Asphyxia

Clinical value of serum cystatin C in diagnosis of acute kidney injury associated with hyperbilirubinemia in full-term newborns

The Clinical Significance of Serum Cystatin Cin Critically Ill Newborns with Normal Serum Creatinine

Predictive Value of Urinary Cystatin C for Mortality in Critically Ill Neonates

Clinical value of urinary cystatin C and interleukin-18 in predicting acute kidney injury in critically ill neonates

Evaluation of Novel Biomarkers for Early Diagnosis of Acute Kidney Injury in Asphyxiated Full-Term Newborns: A Case-Control Study

Detecting Neonatal AKI by Serum Cystatin C

DETECTING NEONATAL AKI BY SERUMCYSTATIN-C

Changes of serum cardiotropin I and cystatin C in preeclampsia and significance thereof

#5359 DETECTING NEONATAL AKI BY SERUM CYSTATIN-C

Urine interleukin-18 and cystatin-C as biomarkers of acute kidney injury in critically ill neonates

Cystatin C in Prediction of Acute Kidney Injury: A Systemic Review and Meta-analysis

[Changes of serum cardiotrophin I and cystatin C in preeclampsia and clinical significance thereof].

Elevated serum cystatin C at continuous renal replacement therapy initiation predicts lack of renal recovery.

Changes of serum cardiotropin Ⅰ and cystatin C in preeclampsia and clinical significance thereof

Serum Cystatin C is Associated with Renal Function Recovery in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy

Elevated Serum Cystatin C at Continuous Renal Replacement Therapy Initiation Predicts Lack of Renal Recovery

Neonatal acute kidney injury and serum cystatin C as its early predictor

Subclinical acute kidney injury is associated with adverse outcomes in critically ill neonates and children